293 related articles for article (PubMed ID: 17660934)
1. A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma.
Swaneveld FH; van Vugt RM; de Boer JP; Dijkmans BA; Lems WF
Clin Rheumatol; 2008 Feb; 27(2):249-51. PubMed ID: 17660934
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
3. [Clinical trial of the monoclonal antibody drug mabthera (Rituximab) in the treatment of non-Hodgkin lymphoma].
Korolenko VO; Gershanovich ML; Leenman EE; Tikhonova VV
Vopr Onkol; 2003; 49(4):459-63. PubMed ID: 14569937
[TBL] [Abstract][Full Text] [Related]
4. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients.
Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ
Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557
[TBL] [Abstract][Full Text] [Related]
5. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma.
Czuczman MS
Semin Oncol; 1999 Oct; 26(5 Suppl 14):88-96. PubMed ID: 10561023
[TBL] [Abstract][Full Text] [Related]
6. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma.
Blasco H; Chatelut E; de Bretagne IB; Congy-Jolivet N; Le Guellec C
Fundam Clin Pharmacol; 2009 Oct; 23(5):601-8. PubMed ID: 19659797
[TBL] [Abstract][Full Text] [Related]
8. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
9. Combination chemotherapy and rituximab.
Czuczman MS
Anticancer Drugs; 2001 Jun; 12 Suppl 2():S15-9. PubMed ID: 11508932
[TBL] [Abstract][Full Text] [Related]
10. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
Miles SA; McGratten M
J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
[No Abstract] [Full Text] [Related]
11. Use of rituximab in combination with conventional chemotherapy for the treatment of non-Hodgkin's lymphoma of the head and neck.
Manolopoulos L; Gomatos IP; Leandros E; Alevizos L; Georgiou N; Giotakis J; Ferekidis E
In Vivo; 2009; 23(3):475-8. PubMed ID: 19454517
[TBL] [Abstract][Full Text] [Related]
12. Rituximab tolerability when given before or after CHOP.
Hannawa IS; Bestul DJ
J Oncol Pharm Pract; 2011 Dec; 17(4):381-6. PubMed ID: 21109616
[TBL] [Abstract][Full Text] [Related]
13. P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II study.
Cocconi G; Franciosi V; Dodero A; Bologna A; Vasini G; De Lisi V; Di Blasio B; Ceci G; Camisa R; Cascinu S
Am J Clin Oncol; 2003 Dec; 26(6):535-42. PubMed ID: 14663368
[TBL] [Abstract][Full Text] [Related]
14. Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy.
Park YH; Sohn SK; Kim JG; Lee MH; Song HS; Kim MK; Jung JS; Lee JJ; Kim HJ; Kim DH
Clin Cancer Res; 2009 Mar; 15(6):2107-15. PubMed ID: 19276283
[TBL] [Abstract][Full Text] [Related]
15. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma.
Lokich JJ
Am J Clin Oncol; 2006 Aug; 29(4):361-3. PubMed ID: 16891862
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
17. [Primary, highly malignant B-cell lymphoma of the prostate. Apropos of a case and review of the literature].
Mounedji-Boudiaf L; Culine S; Devoldère G; Terrier-Lacombe MJ; Kattan J; Cazier A; Farhat F; Bekradda M; Droz JP
Bull Cancer; 1994 Apr; 81(4):334-7. PubMed ID: 7703552
[TBL] [Abstract][Full Text] [Related]
18. Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases.
Wöhrer S; Troch M; Zwerina J; Schett G; Skrabs C; Gaiger A; Jaeger U; Zielinski CC; Raderer M
Ann Oncol; 2007 Apr; 18(4):647-51. PubMed ID: 17218490
[TBL] [Abstract][Full Text] [Related]
19. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients.
van 't Veer MB; de Jong D; MacKenzie M; Kluin-Nelemans HC; van Oers MH; Zijlstra J; Hagenbeek A; van Putten WL
Br J Haematol; 2009 Feb; 144(4):524-30. PubMed ID: 19036081
[TBL] [Abstract][Full Text] [Related]
20. Indolent lymphoma: can rituximab resolve the watch-and-wait debate?
Ross E
J Natl Cancer Inst; 2010 Feb; 102(4):220-1. PubMed ID: 20145214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
